Lucent Soft Gelatin 25mcg

Capsule

Generics : Calcitriol

Manufacturer : Renata Limited

Best Price * TK 100.00

* Delivery will be done in Dhaka city only.

Alternative Product

Capsule Calcitrol Licap - 0.25mcg Square Pharmaceuticals Ltd.

Tk 100.30

Capsule Dicaltrol - 0.25mcg Drug International Ltd.

Tk 12.00

Capsule Colitrol .25 mcg Cap Incepta Pharmaceuticals Ltd.

Tk 10.00

Capsule Lucent Soft Gelatin - 0.25mcg Renata Limited

Tk 10.00

Capsule Caltrol - 0.25mcg Pacific Pharmaceuticals Ltd.

Tk 10.00

More Information About - Lucent Soft Gelatin 25mcg

Description

Generic Name

Calcitriol

Precaution

Idiopathic hypercalcaemia. Pediatric doses must be individualised and monitored under close medical supervision. Coronary disease, renal function impairment and arteriosclerosis, especially in the elderly. Hypoparathyroidism. Excessive dosage of Calcitriol induces hypercalcemia and in some instances hypercalciuria; therefore, early in treatment during dosage adjustment, serum calcium should be determined twice weekly. Patients with normal renal function who are taking Calcitriol should avoid dehydration. Adequate fluid intake should be maintained. Lactation: Enters breast milk; not recommended

Indication

Osteoporosis, Hypoparathyroidism, Hypocalcaemia, Osteomalacia rickets, Renal osteodystrophy, Chronic kidney dialysis.

Contra Indication

Hypercalcaemia; evidence of vitamin D toxicity. Pregnancy (dose exceeding RDA). Lactation.

Dose

N/A

Side Effect

Abdominal pain,Apathy,BUN and creatinine increased,Cardiac arrhythmia,Constipation,Dry mouth,Dehydration,Growth suppression,Headache,Hyperthermia,Hypercalcemia,Hypercholesteremia,Hypermagnesemia,Hyperphosphatemia,Hypertension,Libido decreased,Metallic taste,Muscle or bone pain,Nocturia,Pruritus,Psychosis,Somnolence,Weakness

Pregnancy Category

Name : C

Description

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Mode of Action

Calcitriol promotes calcium absorption in the intestines and retention at the kidneys thus increasing serum calcium levels. It also increases renal tubule phosphate resorption consequently decreasing serum phosphatase levels, PTH levels and bone resorption..

Interaction

Hypermagnesaemia may develop in patients on chronic renal dialysis. Hypercalcaemia in patients on digitalis may precipitate cardiac arrhythmias. Intestinal absorption of calcitriol may be reduced by cholestyramine and colestipol. Phenytoin, barbiturates may decrease the T1/2 of calcitriol. May develop hypercalcaemia with thiazide diuretics.

Pregnancy Category Note

Pregnancy category: C Lactation: Enters breast milk; not recommended

Adult Dose

Adult: Capsule: The optimal daily dose of Calcitriol must be carefully determined for each patient on the basis of the serum calcium level. Calcitriol can be administered orally either 0.25 mcg or 0.50 mcg. Postmenopausal osteoporosis The recommended dosage is 0.25 mcg twice daily or 0.50 mcg once daily. Serum creatinine levels should be determined at 4 weeks, 3 and 6 months and 6 monthly intervals thereafter. Renal osteodystrophy (Dialysis patients) The recommended initial dose of Calcitriol is 0.25 mcg/day. Patients with normal or only slightly reduced serum calcium levels may respond to Calcitriol doses of 0.25 mcg every other day. Most patients undergoing hemodialysis respond to doses between 0.5 and 1 mcg/day. Hypoparathyroidism & Rickets The recommended initial dosage of Calcitriol is 0.25 mcg/day given in the morning. If a satisfactory response is not observed, the dose may be increased at 2 to 4 week intervals. Predialysis patients: The recommended initial dosage of Calcitriol is 0.25 mcg/day in adults. This dosage may be increased if necessary to 0.5 mcg/day. Injection The recommended intravenous initial dose of Calcitriol injection, depending on the severity of the hypocalcemia and/or secondary hyperparathyroidism, is 1 mcg (0.02 mcg/kg) to 2 mcg administered three times weekly, approximately every other day. Doses as small as 0.5 mcg and as large as 4 mcg three times weekly have been used as an initial dose. If a satisfactory response is not observed, the dose may be increased by 0.5 to 1 mcg at two to four week intervals.

Child Dose

Chronic Renal Dialysis Associated Hypocalcemia 0.25-2 mcg/day PO qDay Hypoparathyroidism/Pseudohypoparathyroidism <1 year: 0.04-0.08 mcg/kg PO qDay 1-5 years: 0.25-0.75 mcg PO qDay >6 years: 0.5-2 mcg PO qDay Familial Hypophosphatemia Initial: 0.015-0.02 mcg/kg PO qDay Maintenance: 0.03-0.06 mcg/kg PO qDay No more than 2 mcg PO qDay Secondary Hyperparathyroidism in Moderate to Severe Kidney Disease <3 years: 0.01-0.015 mcg/kg/day >3 years: 0.25 mcg/day PO; may increase to 0.5 mcg/day Hypocalcemia in Premature Infants 1 mcg qDay PO for 5 days

Renal Dose

N/A

Administration

May be taken with or without food. May be taken w/ meals to reduce GI discomfort.

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.